Adaptive Biotechnologies Corporation Common Stock (ADPT) is a publicly traded Healthcare sector company. As of May 21, 2026, ADPT trades at $13.82 with a market cap of $2.03B and a P/E ratio of -41.23. ADPT moved +7.64% today. Year to date, ADPT is -13.67%; over the trailing twelve months it is +49.15%. Its 52-week range spans $4.27 to $20.76. Analyst consensus is strong buy with an average price target of $20.17. Rallies surfaces ADPT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ADPT SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $13.82 |
| Market Cap | $2.03B |
| P/E Ratio | -41.23 |
| EPS | $-0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.76 |
| 52-Week Low | $4.27 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $295.41M |
| Net Income | $-49.64M |
| Gross Margin | 75.26% |
8 analysts cover ADPT: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.17.